Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer

BACKGROUND: Evidence for use of second-line immunosuppressants for immune-related adverse events (irAEs) is inadequate. Therefore, a multicenter analysis should assess the efficacy of second-line immunosuppressants for severe irAEs associated with different malignant diseases. METHODS: This descript...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogusu, Shinsuke, Harutani, Yuhei, Tozuka, Takehiro, Saito, Ryota, Koyama, Junji, Sakamoto, Hiroaki, Sonoda, Tomoaki, Tsuchiya-Kawano, Yuko, Oba, Tomohiro, Kudo, Keita, Gyotoku, Hiroshi, Nakatomi, Katsumi, Ariyasu, Ryo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576678/
https://www.ncbi.nlm.nih.gov/pubmed/37638979
http://dx.doi.org/10.1007/s00262-023-03528-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576678/
https://www.ncbi.nlm.nih.gov/pubmed/37638979
http://dx.doi.org/10.1007/s00262-023-03528-x

Ejemplares similares